insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr
PRESS RELEASE
June 15, 2010
Investor Relations Contacts:

Brandi Floberg
The Piacente Group
212-481-2050
ir@arrowres.com

 


ARROWHEAD TO HOLD ANNUAL MEETING JUNE 16, 2010;
CEO PRESENTATION AVAILABLE VIA WEBCAST


PASADENA, Calif. –June 15, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Annual Meeting of Stockholders will be held on Wednesday, June 16, 2010 at 10:00 am PT at the Sheraton Pasadena, 303 E. Cordova Street, Pasadena, CA. Following the meeting, at 10:15 am PT, Arrowhead’s CEO, Dr. Christopher Anzalone, will give an overview of the Company’s accomplishments for the last fiscal year, the evolution of its strategy, and goals for 2010. The presentation will be available via webcast on the Company's website at www.arrowheadresearch.com. A replay of the webcast will be available after the conclusion of the call. The webcast archive will remain available for 90 days.

 




About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.